INTRODUCTION
Non-Hodgkin B-cell lymphomas (NHLs) are a heterogeneous group of diseases, each with its own histology, biology, and clinical course. More than 35 different subtypes have been described by the World Health Organization, and these can be further clinically classified as aggressive or indolent. 1 Follicular lymphoma accounts for the majority of indolent NHLs, with extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), mantle cell lymphoma, and splenic and nodal marginal zone lymphomas accounting for the remainder. 2 NHLs are staged according to the Ann Arbor system and its later Cotswolds modification, with the majority of patients presenting with advanced stage disease ( Table 1) . 3 Treatment selection is prescribed by disease stage and clinical symptoms, and options include locoregional radiotherapy for localized disease, watchful waiting in asymptomatic advanced stage patients, and systemic therapy for symptomatic patients and specific types of indolent NHLs. [4] [5] [6] Staging of indolent lymphoma includes clinical, imaging, and histological data. The role of positron emission tomography (PET) in the workup of patients with indolent lymphoma has been a controversial topic. Although highgrade lymphomas are mostly fludeoxyglucose (FDG)-avid and can be readily staged and surveilled with FDG-PET/computed tomography (CT), conflicting data have been published regarding the FDG avidity of different low-grade lymphoma subtypes. 7 Although some subtypes of indolent lymphoma (eg, small lymphocytic lymphoma) may not be FDG-avid, most indolent NHLs and nearly all follicular lymphomas (the most common indolent subtype) are FDG-avid. [7] [8] [9] In recent years, researchers have attempted to assess the impact of FDG-PET/CT on staging of patients with indolent lymphoma and on the ability of PET/CT to predict patient outcome. Most studies were retrospective and were performed in a single center. In a prospective multicenter study including 74 patients with indolent lymphoma, Scott et al 10 reported that PET (with or without fused CT data) upstaged presumed limited stage disease in 28% of patients and had an impact on patient management in 34% of cases. Other retrospective studies on follicular and other indolent lymphomas have shown disease upstage after PET in 10.6%-46.8% of patients, with approximately 10%-31% of patients being upstaged from limited to advanced stage disease. [11] [12] [13] [14] [15] [16] [17] [18] A recent systematic review on the role of PET in staging of follicular lymphoma, including 7 studies with a total of 349 patients, suggested that overall methodological quality of available studies was poor. This review found a pooled proportion of patients upstaged by PET of 18.7%. 19 Based on existing data, a consensus statement of the International Conference on Malignant Lymphomas Imaging Working Group (MLIWG) published in 2014 recommended the use of PET/CT in staging of all FDG-avid lymphomas, including FDG-avid indolent subtypes. 20, 21 The purpose of this multicenter prospective study was to measure the clinical impact of pretreatment FDG-PET/CT on the staging and management of untreated, apparent limited stage indolent lymphoma patients who are being considered for curative radiation therapy.
PATIENTS AND METHODS

Study Design and Data Sources
The Ontario PET Registry (OPR) for indolent lymphomas was a multicenter prospective registry study funded by the Ontario Ministry of Health and Long-Term Care. Registry data was collected by Cancer Care Ontario (CCO) as a continuation of studies initiated by the Ontario Steering Committee for Positron Emission Tomography Evaluation (also known as the PET Steering Committee). The drive behind the launch of this registry was the need to strengthen existing evidence for the use of PET/CT in the staging and management of patients with indolent lymphoma, as an adjunct to the standard staging procedures which include clinical and conventional radiologic investigations. The registry was designed to prospectively measure the clinical impact of PET/CT performed in this patient population in multiple centers across the province. PET/CT was interpreted locally at each participating center. Similarly, the decision of whether to treat or observe a patient was made by the local oncologist, with all available clinical and imaging data including PET/CT staging. The outcome measures included comparison of disease stage and intended treatment modality before and after PET/CT, as well as change in actual treatment received compared with planned treatment after PET/CT. Analyses were performed for the cohort as a whole, and-to more specifically characterize the impact of PET/CT for more homogeneous histology-for the subset of patients with the dominant indolent lymphoma subtype, follicular lymphoma.
The inclusion criteria for this registry were (1) histological confirmation of nodal follicular or other indolent NHLs; (2) apparent or possible limited stage disease as per conventional clinical and radiological staging procedures (CT); and (3) consideration for curative radiation therapy if limited stage is confirmed. As a prerequisite for inclusion in the registry, referring physicians were required to document the specific histologic subtype, pre-PET/CT stage as per available clinical and CT data; and pre-PET/CT planned treatment. Patients with indeterminate findings for limited or advanced stage on conventional workup before PET/CT who were candidates for curative therapy if limited stage disease was confirmed were included in this registry. For these patients, a specific stage (I-IV) was assigned by the referring oncologist according to the best clinical judgment and treatment plan, as if PET/CT was not available. To avoid selection bias, all patients from all centers who were eligible and were referred for PET/CT were included in the registry.
Patients were scanned in 1 of 10 PET/CT centers across the Canadian province of Ontario between May 1, 2012, and December 31, 2015. After PET/CT was performed, the revised post-PET/CT stage was recorded by the reporting nuclear medicine physician according to the Ann Arbor classification (Cotswolds modification) or as equivocal if PET/CT identified an indeterminate lesion that-if proven positive for lymphoma on further workup-would upstage the patient. In addition, a revised treatment plan was documented by the referring oncologist with the PET/CT results (ie, post-PET/CT treatment intent).
To evaluate the actual impact of PET/CT to patient management, we performed a data linkage of OPR data to provincial administrative databases using health insurance numbers. To obtain patient demographic data, OPR was linked to the Ontario Cancer Registry (OCR), which includes information on all newly diagnosed cases of lymphoma in Ontario. To retrieve treatment data, OPR was also linked to CCO's Activity Level Report database, which contains patient-level activity data from Ontario's Integrated Cancer Programs. This data was available for all activities occurring before August 31, 2015.
Data collection, analysis, and presentation of these results was conducted in accordance with CCO's designation as a "prescribed entity" for the purposes of section 45(1) of the Personal Health Information Protection Act (2004). As a prescribed entity, CCO is able to collect personal health information for the purpose of analysis or compiling statistical information with respect to the management of, evaluation or monitoring of, the allocation of resources to, or planning for all or part of the health system, including the delivery of services. CCO's information management practices are reviewed on a triennial basis by the Information and Privacy Commissioner of Ontario. PET/CT scans were performed in 10 participating Ontario centers using local departmental oncology protocols, with a non-contrast-enhanced low-dose CT preceding PET acquisition and whole-body PET/CT scanning in the supine position from the skull base to the upper thighs. All scans were interpreted locally by the nuclear medicine physician with knowledge of the clinical history and access to correlative imaging studies.
Statistical Analysis
Differences in proportions of patients were assessed for significance using chi-square tests, where P < .05 was considered significant. All tests were 2-tailed except for the proportion of patients planned to receive treatment before and after PET/CT, where a 1-tailed test was used. Confidence intervals of the difference in ratios are also given. Statistical analysis was performed using R statistical software version 3.1.2 (2014).
RESULTS
Study Population
The registry included a total of 197 patients (104 men and 93 women) with newly diagnosed indolent lymphoma with a median age of 63 years (range, 17-90 years). 
Post-PET/CT Treatment Intent and Actual Management
Entire cohort
As per the registry criteria, the pre-PET/CT treatment plan for all patients was radiation therapy. Post-PET/CT data linkage to treatment data available through CCO's Activity Level Report was available for patients treated until August 31, 2015 (155 of 197 [78.7%] patients). The post-PET/CT treatment plan, as documented by referring physicians after receiving the PET/CT stage, was compared with the actual treatment delivered and is presented in Table 4 . The distribution of received treatment by post-PET/CT disease stage is detailed in Table 5 . The change in proportion of patients planned for active treatment before PET/CT (radiation therapy, as per inclusion criteria) versus after PET/CT was significant, with only 95 of 155 (61.3%) patients planned to receive active treatment post-PET/CT (95% CI, 21.0 to 20.32; P < .0001); however, only 66 of 155 (42.6%) patients were actually treated, all of whom had follicular lymphoma (95% CI, 0.08-0.30; P 5 0.001). The greatest variance between planned post-PET/CT treatment and actual treatment was in the group of patients being considered for radiotherapy as a single treatment modality. Fifty-nine of 155 patients (38.1%) were planned for radiotherapy as a single treatment modality after PET/CT; however, only 34 of the entire cohort ultimately received radiotherapy (95% CI, 0.06-0.26; P 5 .002). Of the patients who received radiotherapy, most had confirmed limited stage follicular lymphoma stage post-PET/CT (27 of 34 [79.4%] patients).
Follicular lymphoma cohort
Post-PET/CT data linkage was available for 121 of 150 (80.1%) patients with follicular lymphoma. There were 71 of 121 (58.7%) patients who were planned to receive treatment after PET/CT (95% CI, 21.0 to 20.34; P < .0001), and most of them were ultimately treated (66 of 71 [92.9%] patients). Consistent with the findings for the entire cohort, the greatest discrepancy between post-PET/ CT treatment intent and actual treatment delivered for the subset of patients with follicular lymphoma was in the group planned for single-modality radiotherapy (Table 4) ; however, when assessing this cohort independently, this change was no longer statistically significant. Forty-three of 121 (35.5%) patients were planned for radiotherapy as a single treatment modality after PET/CT, and 34 of 121 (28.1%) patients ultimately received treatment (95% CI, 20.04 to 0.20; P 5 .214), as detailed in Table 6 .
DISCUSSION
Therapy choice for patients diagnosed with indolent lymphoma is dependent on accurate disease staging. In this prospective study, we were able to demonstrate the impact of PET/CT on the initial staging and management of patients with indolent lymphoma. Our data show that 1 in 4 patients with apparent limited stage disease, as determined through clinical and CT assessment, were shown to have advanced disease on PET/CT, which is consistent with previously published data. [11] [12] [13] [14] [15] [16] [17] [18] [19] Although our study did not target patients with overt advanced stage disease, referring physicians could assign an advanced stage pre-PET/CT if this reflected intended treatment (<12% of the entire patient cohort). This facilitated PET/CT scans for patients with equivocal CT for advanced stage when the patient would be a candidate for curative radiotherapy if assigned a limited stage post-PET/CT. The actual rate of downstaging is therefore difficult to determine with our data, although from the small number of patients with possible advanced disease pre-PET/CT (n 5 23), nearly 1 in 6 patients (n 5 4) were downstaged to limited disease after PET/CT.
Stage migration after PET/CT resulted in a change in treatment intent and actual therapy received in a large proportion of patients. Although planned radiotherapy was one of the criterion for inclusion in the registry, this remained the plan after the PET/CT scan for only 41.9% of patients. Furthermore, only 24.5% of the patients in the cohort ultimately received radiation, either as a single modality or in conjunction with chemotherapy, and a majority of patients (57.4%) did not receive any treatment and were clinically surveilled. The impact on patient management suggested by the results of the current study may be greater than that suggested previously (31% as reported by Scott et al 10 ). When considering the relapse rate of patients who receive radiotherapy (up to 50% after 10 years in patients with follicular lymphoma) and the potential morbidity associated with this treatment, it is evident that pretreatment PET/CT plays an important role in the appropriate selection of patients for this mode of management.
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Staging PET/CT is likely to have further impact on patient management, which was not captured in this registry. Even for patients in whom disease stage was not altered post-PET/CT, actual treatment delivery such as the definition of radiation fields may have changed. Therefore, the overall impact of PET/CT on patient management is likely underestimated in the current study.
There are a few additional observations from this study. First, 14.2% of patients who were assigned a specific disease stage pre-PET/CT were found to have equivocal findings on PET/CT that would potentially impact management decision necessitating further investigation, such as biopsy. The relatively high number of equivocal cases post-PET/CT may be due to the inherent limitation of PET/CT in confirming malignant nodal involvement in locations where reactive nodes are commonly encountered, such as jugulodigastric, axillary, or groin lymph nodes. When metabolically active, histological evaluation may be needed to confirm or exclude a further site of disease, although the registry study design prevented us from capturing patient-specific biopsy data. However, given the rate of change in management plan after PET/ CT, the benefit of performing PET/CT in indolent lymphoma staging may still be substantial.
A further interesting observation from our results is that approximately 20% of patients underwent a watchful waiting approach compared with the post-PET/CT management plan (38.7% pre-PET/CT versus 57.4% post-PET/CT). Given the design of the study, which did not mandate a specific mode of management, we can only suggest potential explanations for this finding. First, because there are similar outcomes for various treatment strategies, there may be patient or physician preference for a specific approach. 23 Furthermore, radiotherapy may be deferred after weighing in the potential specific treatment toxicity (for example, bowel toxicity related to radiotherapy directed at abdominal lymphadenopathy) and associated patient comorbidities. In our cohort, approximately 43% of patients with early stage follicular lymphoma were treated with radiotherapy, similar to the results of the National LymphCare Study. 23 This study has a few major strengths. Study design was prospective, and to date represents the largest cohort in published literature assessing the impact of staging with PET/CT as well as the downstream impact to treatment decisions for patients with indolent lymphoma. This was also extended to demonstrate actual treatment received by patients. It thus solidifies the evidence for current recommendations of the MLIWG on the use of PET/CT in the staging of patients with FDG-avid indolent lymphomas, and documents the impact on patient management, especially when radiotherapy is being considered as a sole modality of treatment. Moreover, because the study was designed as a multicenter, multireader prospective study with PET/CT interpreted locally, the results likely reflect actual clinical impact of PET/CT on staging and management of this patient population in routine practice. In addition, unlike previous studies that included either PET or mixed PET and PET/CT data, our study was performed using only integrated PET/CT.
There are several limitations to this study. Because of the limitations of administrative databases, actual treatment received was available for most but not all patients; however, the findings where data were available is compelling. Additionally, follicular lymphoma comprised the majority of histological subtypes of indolent lymphoma in this study; therefore, although we were able to comment on the impact of PET/CT overall and for the subset of patients with follicular lymphoma, conclusions regarding other subtypes may not be as robust. Of note, in our cohort, all patients who ultimately received treatment had follicular lymphoma. This is likely due to its prevalence compared with other indolent subtypes, as well as due to underrepresentation of non-FDG-avid indolent lymphomas (eg, small lymphocytic lymphoma) and other subtypes not primarily treated with radiotherapy (eg, mucosa-associated lymphoid tissue lymphoma). Furthermore, our study did not compare patient outcome, including rate of remission, or disease control after radiotherapy when PET/CT or CT were used for patient selection and treatment planning. However, given migration to advanced stage after PET/CT in a significant proportion of patients, PET/CT is likely to better select patients for radiotherapy with curative intent and may improve overall outcome in the treated cohort. Finally, the cost-effectiveness of adding PET/CT to the workup of patients with indolent lymphoma being considered for curative intent radiotherapy was not addressed in this study, but may be taken into consideration when designing future prospective trials.
In conclusion, PET/CT has a significant impact on staging and management of patients with apparent limited stage indolent lymphoma being considered for curative radiotherapy. Routine PET/CT should be routinely incorporated into the workup of these patients.
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